Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company specializing in next-generation cancer therapies, has announced its participation in the upcoming MedInvest Biotech and Pharma Investor Conference. The event will take place on March 27-28, 2025, at Cooley's law office in New York City.

The company's management team will deliver a corporate overview presentation on March 28th at 9:40 a.m. Eastern time. Additionally, they will engage in one-on-one meetings with registered investors and conference attendees throughout the event. The presentation materials will be made accessible on Processa's website.

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley’s law office in New York City.

Management will present a corporate overview on Friday, March 28^th at 9:40 a.m. Eastern time, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. The presentation will be available on Processa’s website.

For more information about the MedInvest Biotech and Pharma Investor Conference, please click here.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.

For more information, visit our website at www.processapharma.com.

Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com

# # #

FAQ

When and where is Processa Pharmaceuticals (PCSA) presenting at the MedInvest Conference?

Processa will present on March 28th, 2025, at 9:40 a.m. Eastern time at Cooley's law office in New York City.

What type of meetings will PCSA management conduct at the MedInvest Conference?

Management will conduct one-on-one meetings with registered investors and attendees throughout the conference.

Where can investors access Processa's MedInvest Conference presentation materials?

The presentation will be available on Processa Pharmaceuticals' website.

What is Processa Pharmaceuticals' (PCSA) current development focus?

Processa is a clinical-stage pharmaceutical company focused on developing next generation cancer therapies with improved efficacy and safety.